The trusted DNA provider in the battle against cancer – we are
more than just a DNA provider
Cancer has spurred relentless efforts by researchers worldwide to uncover its secrets, develop breakthrough therapies, and ultimately improve patient outcomes. At Twist we are proud to be at the forefront of this battle, offering innovative custom DNA solutions—from library preparation kits to target enrichment panels to gRNA libraries to therapeutic partnering - we are here to help inform the path forward. Twist Bioscience is revolutionizing cancer diagnostics and treatment with a comprehensive suite of tools across the cancer continuum.
Highlighted Applications
Early Screening Solutions for Enhanced Detection
Tools and techniques that enable earlier detection of cancer have the potential to improve survival rates as treatment options could be more likely to be successful. Liquid biopsy-based early screening tools, however, face both biological and analytical challenges due to low tumor DNA shedding and the low analytical sensitivity of many existing approaches. Hybrid capture-based enrichment combined with computational biology and machine learning approaches, allows researchers to overcome these challenges, delivering highly efficient and uniform analysis of the targets of interest that may lead to early and accurate identification of cancer signals. With Twist’s portfolio of research products we can help overcome these challenges with highly precise and scalable target enrichment solutions, high quality library preparation, and the flexibility to support your research.
Empowering researchers with tools to characterize various types of cancer
Our advanced genomic profiling technologies, such as targeted enrichment panels and high-fidelity DNA synthesis, provide high accuracy and coverage, supporting the comprehensive interrogation of tumor genomes. Twist Bioscience's commitment to innovation extends to the development of custom panels, enabling tailored sequencing approaches for precise biomarker identification and validation. With our products, researchers can gain a comprehensive view of the genomic landscape, which can support breakthroughs in the understanding of tumor heterogeneity.
Solutions to help guide therapy selection for personalized medicine
By leveraging our genomic profiling technologies, including Twist targeted enrichment panels and custom DNA synthesis capabilities, researchers can catalog the unique genetic makeup of individual patients' tumors. This data can support the study of pharmacogenomics and supports the development of genetics-informed medicine. Twist's NGS products—born from our high-fidelity DNA synthesis platform—facilitate both broad surveys and in depth analyses of pharmacogenetic variants. By offering products that allow researchers to reliably delve into tumor genetics, Twist Bioscience is helping to advance precision oncology research towards a future where treatment options may be finely tuned to the specific genomic characteristics.
Products to support developing highly sensitive assays
In the area of cancer monitoring and detection, Twist Bioscience offers products that can be specifically designed for Minimal Residual Disease (MRD) research. Leveraging our genomics technologies, including targeted enrichment panels and our DNA synthesis platform, Twist Bioscience can help enable researchers to build highly sensitive and specific assays for detecting minute traces of residual disease. Our NGS products help capture and sequence fragments of circulating tumor DNA (ctDNA), supporting researchers to further understand ctDNA dynamics and utility in MRD. With Twist Bioscience, researchers gain a powerful toolkit to support monitoring for residual disease and help to bring us closer to a future where sequencing technology may enable early intervention and personalized treatment strategies.
Liquid Biopsy
Following curative treatment, tumor cell populations may drop precipitously. Traditionally, imaging-based technology has been used to monitor for tumor recession. However, there is a gap between these technologies’ limit of detection and the point where cancer is truly gone. In this gap, residual cancer cells can persist and eventually expand. Minimal Residual Disease (MRD) testing via liquid biopsy has become a promising approach to sensitive detection of those malignant cells that persist beyond the reach of imaging technologies.
To enable such sensitive detection, researchers need tools that allow them to efficiently sift through cell free DNA and sensitively pick out circulating tumor DNA fragments (ctDNA). Twist empowers researchers with highly accurate and uniform synthesis of target capture probes for MRD applications. Twist’s industry leading accuracy means a reduced chance of off-target binding and highly uniform probe synthesis reduces the chances of rare fragment drop-out. Together, these features mean that Twist target enrichment panels—such as the Twist MRD 500 panel—can be used for highly efficient and sensitive ctDNA detection, enabling the development of advanced MRD assays.
Don’t see your application?
Get in touch with one of our field application scientists to identify the best solutions for your project
Detecting Cancer’s Methylation Fingerprint in Blood Plasma
Since 2012, Universal Diagnostics has been working to revolutionize early cancer detection. To make their high-throughput, NGS-based assay a reality, they needed a reputable, trustworthy source of custom panels for hybrid capture. They found the source they were looking for — as well as an enthusiastic research partner — in Twist Bioscience.
Product Sheet
Flyer
